Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is a multi-center Phase 2 study to determine the safety and efficacy of sepantronium
bromide (SepB) in adult patients with relapsed or refractory high-grade B-cell lymphoma